Clinical trials: Virologic Failure
HIV Infection
Antiretroviral Therapy and Extreme Weight
The concentration of the third agent in antiretroviral therapy [Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI), or boosted Protease inhibitor (PI) ] is different according to the body weight or body composition and…
- Trial name
- EXTATIC (NCT01805427)
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Hopital Lariboisière
HIV-1
An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).
The purpose of this trial is to evaluate the long-term safety and tolerability of TMC125 200 mg twice daily as part of an antiretroviral therapy including TMC114/rtv and an investigator selected optimized background in HIV-1…
- Trial name
- NCT00359021
- Testing
- TMC125
- Where
- 72 sites in United States, Argentina and 12 more
- Volunteers
- 503 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Seropositivity, HIV Infection
Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART
This is an open-label, prospective, randomized, controlled study of the safety and efficacy including clinical, immunologic, and virologic assessments of adding Ampligen to "HAART" in HIV infected patients with CD4 counts >300…
- Trial name
- NCT00035581
- Testing
- poly I-poly C12U
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- AIM ImmunoTech Inc.
HIV, Depression
Progress Adult Study
The purpose of this study is to study the HIV disease progression in HIV-infected Thai Adult.
- Trial name
- NCT01328275
- Testing
- standard regimens according to the Thai Ministry of Public Health national guidelines
- Where
- 3 sites in Thailand
- Volunteers
- 5,600 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Human Immunodeficiency Virus (HIV)-1 Infection, HIV-1 Subtype A6 Infection
Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study
This study evaluates the real-world effectiveness and safety of a long-acting injectable HIV treatment consisting of cabotegravir and rilpivirine in people living with HIV-1.
- Conditions
- Human Immunodeficiency Virus (HIV)-1 Infection, HIV-1 Subtype A6 Infection, HIV-1 Subtype B Infection, Virologically Suppressed HIV-1 Infection Receiving Long-Acting Antiretroviral Therapy
- Trial name
- LACRIS (NCT07370649)
- Testing
- Cabotegravir Plus Rilpivirine Long-Acting Injectable
- Where
- 7 sites in Czechia, Germany and 1 more
- Volunteers
- 250 people
- Sponsor
- Pomeranian Medical University Szczecin
HIV, HIV Infections
Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
Since the first line antiretroviral (ARV) treatment is now largely accessible in the Sub-Saharian Africa countries, documentation of virological failure, drug resistance patterns and second line treatment evaluation are still to…
- Trial name
- 2LADY (NCT00928187)
- Testing
- emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line), abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line), emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
- Where
- 3 sites in Burkina Faso, Cameroon and 1 more
- Volunteers
- 454 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1
Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects
For HIV-infected individuals with highly resistant viruses, higher drug levels may be required to block the virus. This study investigates that concept by comparing the efficacy of standard fosamprenavir/ritonavir to an increased…
- Trial name
- NCT00144833
- Testing
- fosamprenavir/ritonavir (700mg/100mg BID), fosamprenavir/ritonavir (1400mg/100mg BID), fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID)
- Where
- 42 sites in Australia, Belgium and 7 more
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
HIV Infections
Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir
The purpose of this study is to see if 3 anti-HIV drug combinations are safe and effective in patients who have failed previous anti-HIV treatments using nelfinavir (NFV).
- Trial name
- NCT00006326
- Testing
- Indinavir sulfate, Ritonavir, Delavirdine mesylate
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Agouron Pharmaceuticals
HIV Infections
Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults
Highly active antiretroviral therapy (HAART) has led to better health and survival rates among people with HIV/AIDS. The purpose of this study was to measure the effect of trained partner supervision when taking medication versus…
- Trial name
- NCT00608569
- Testing
- Lopinavir/ritonavir, Emtricitabine/Tenofovir disoproxil fumarate, Tenofovir disoproxil fumarate
- Where
- 9 sites in Botswana, Brazil and 6 more
- Volunteers
- 529 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV1 Infection, HIV Infections
Prospective Evaluation Among Patients Infected by HIV 1 in Virological Failure Owing to Lack of Compliance, of the Benefit in Terms of Compliance of an Optimised Antiretroviral Treatment With Enfuvirtide (Fuzeon) Associated With Two Active Molecules
In case of lack of compliance in HIV1 patients, the investigators hope to prove that enfuvirtide injection during almost 3 months, with nurse help at home and therapeutic education may contribute to obtain a good compliance more…
- Trial name
- AMPHORE (NCT00937729)
- Where
- France
- Volunteers
- 4 people
- Sponsor
- University Hospital, Rouen
Treatment Failure, HIV or AIDS, CD4 Cell Counts
Effectiveness of Efavirenz-based Regimen in HIV-1-infected Patients With Nevirapine Hypersensitivity
The primary objective of this study is to compare the effectiveness of EFV-based regimens in HIV-1-infected patients who; (1) were previously allergic to NVP and stopped all ARV simultaneously; (2) were previously allergic to NVP…
- Trial name
- NCT01044810
- Testing
- Efavirenz-based regimens
- Where
- Thailand
- Volunteers
- 559 people
- Sponsor
- Bamrasnaradura Infectious Diseases Institute
HIV, Metabolic Syndrome
Comorbidities and Virologic Outcome Among Patients on Anti-retroviral Therapy in Rural Lesotho
This study is conducted in a cohort of HIV-positive patients on first-line anti-retroviral therapy (ART) in rural health facilities in Lesotho, Southern Africa.
- Conditions
- HIV, Metabolic Syndrome, Depression, Alcoholism
- Trial name
- NCT02126696
- Where
- 2 sites in Lesotho
- Volunteers
- 1,754 people
- Sponsor
- Swiss Tropical & Public Health Institute
Chronic Hepatitis C
Re-treatment of HCV Following DAA Failure
HCV infection is treated with oral drugs, termed as 'direct-acting anti-viral agents' (DAAs). In India, four DAAs are available (sofosbuvir [SOF], daclatasvir [DCV], ledipasvir [LDV] and velpatasvir [VEL]).
- Trial name
- NCT03483987
- Testing
- Sof+Ledi+R arm, Sof+Ledi+R+Peg-IFN arm, Sof+Dacla+R arm
- Where
- 2 sites in India
- Volunteers
- 18 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
HIV, Hepatitis B
EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV
The EuroSIDA study is a prospective observational cohort study of 23,000+ patients followed in 100+ clinics in 35 European countries, Israel and Argentina.
- Conditions
- HIV, Hepatitis B, Hepatitis C, AIDS
- Trial name
- EuroSIDA (NCT02699736)
- Where
- 110 sites in Argentina, Austria and 34 more
- Volunteers
- 23,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
HIV Infection
Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure
This study is a 48-week study to evaluate the efficacy and safety of an investigational regimen combining FDA approved HIV drugs in antiretroviral-experienced subjects failing on their first highly active antiretroviral therapy…
- Trial name
- NCT00038506
- Testing
- abacavir/lamivudine/zidovudine, tenofovir
- Where
- 27 sites in United States
- Volunteers
- 100 people
- Sponsor
- ViiV Healthcare
HIV Infections, AIDS
A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa
The RESOLVE trial is an open, parallel arm, randomized clinical trial which aims to determine the optimal strategy for management of virologic failure on antiretroviral therapy (ART) with tenofovir, lamivudine, and dolutegravir…
- Conditions
- HIV Infections, AIDS, Virologic Failure
- Trial name
- RESOLVE (NCT05373758)
- Testing
- Standard of Care treatment strategy, Individualized Care treatment strategy, Immediate Switch
- Where
- 3 sites in South Africa, Uganda
- Volunteers
- 648 people
- Sponsor
- Massachusetts General Hospital
HIV
Non-Interventional Observational Retrospective Study to Evaluate Doravirine Based-regimens in HIV Infected Aged Patients (DORAge).
The HIV-infected population is aging due to the success of combination antiretroviral therapy, which prolongs survival, as well as the growing number of newly diagnosed cases in adults 50 years old and over.
- Trial name
- DORAge (NCT05202613)
- Testing
- Doravirine
- Where
- Italy
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
HIV-1-infection
BFTAF Elderly Switch Study
BACKGROUND: Current Kenya National Anti-retroviral (ARV) Guidelines and World Health Organization (WHO) Guidelines recommend first-line therapy of tenofovir disoproxil fumarate (TDF), lamivudine (3TC) and dolutegravir (DTG) for…
- Trial name
- BFTAF (NCT05243602)
- Testing
- Switch to B/F/TAF, Continue current regimen
- Where
- 2 sites in Kenya
- Volunteers
- 520 people
- Sponsor
- University of Nairobi
HIV Infections
Optimised Electronic Patient Records to Improve Clinical Monitoring of HIV-positive Patients in Rural South Africa
In our formative research, analysis of antiretroviral treatment (ART) data manually entered in the Three Interlinked Electronic Registers (TIER.Net) showed poor viral load monitoring (VLM) and inadequate management of virological…
- Trial name
- MONART (NCT05071573)
- Testing
- Optimised electronic patient records
- Where
- South Africa
- Volunteers
- 1,500 people
- Sponsor
- University of Sussex
HIV
National Evaluation of PI-based 2nd Line Efficacy in Cambodia
Medium and long term efficacy of PI-based 2nd line antiretroviral (ARV) therapy in Cambodia is poorly documented when the numbers of patients on treatment and their duration are increasing.
- Trial name
- NCT01801618
- Where
- 13 sites in Cambodia
- Volunteers
- 15,001,351 people
- Sponsor
- ANRS, Emerging Infectious Diseases